Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 &

Status Completed

Clinical Trial Summary

This study is a retrospective pharmacological study, of a historical cohort. Collection of Retrospective data from February 2020 to 30 September 2021 The index date is the date of COVID-19 positive PCR test. The data will be collected until last news (last clinical visit or death). There are no defined study visits. In the course of the study, the clinical data recorded are those corresponding to the standard medical procedure. The goal of this study is to assess the impact on continuing or stopping adalimumab treatment on the occurrence of a severe COVID-19 (Coronavirus Disease 2019) in patients with Immune-Mediated Inflammatory Disease (IMID), during the first month after the diagnosis of SARS-CoV-2 infection. To our knowledge, no comparisons have been performed between IMID patients stopping or not their maintenance treatment. In the context of the COVID-19 epidemic, the goal is to minimize the risk of disease flare while simultaneously minimizing the risk of severe COVID-19. In this study, we hypothesized that patients treated by adalimumab for IMID might not be susceptible to severe COVID-19 disease course.

Clinical Trial Description

Immune-mediated inflammatory disease (IBD or rheumatic disease) patients treated with adalimumab with positive PCR COVID-19 diagnosis will be enrolled by physicians. There will be four predefined and balanced group: 1. Adalimumab withdrawal in patients with IBD 2. Adalimumab continuation in patients with IBD 3. Adalimumab withdrawal in patients with RA, PsA, axSpA, and nrxSpA 4. Adalimumab continuation in patients with RA, PsA, axSpA, and nrxSpA n = 312 subjects for groups 1+3 together and 312 subjects for groups 2+4 together. All data will be described by percentages (categorical variables) and mean +/- standard deviation and quartiles (continuous variables). The median time of follow-up survival data will also be detailed for each event of interest (admission to intensive care unit, need to a mechanical ventilation during hospitalization, death). Kaplan Meier curve will describe the probability of the occurrence of a severe SARS-CoV-2 infection (see primary endpoint for definition). Time to analysis - better define - time to severity of the event. Occurrence (yes/no) ;

Study Design

Related Conditions & MeSH terms

Inflammatory Bowel Diseases

Clinical Trial Details

NCT number	NCT05706038
Study type	Observational
Source	IRCCS San Raffaele
Contact
Status	Completed
Phase
Start date	April 27, 2022
Completion date	October 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04046913` - The ADDapt Diet in Reducing Crohn's Disease Inflammation	N/A
Active, not recruiting	`NCT04989907` - A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Switzerland
Recruiting	`NCT05316584` - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy	N/A
Active, not recruiting	`NCT04990258` - A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
Enrolling by invitation	`NCT06015789` - Self-care in Patients Affected by Inflammatory Bowel Disease and Caregivers' Contribution to Self-care
Recruiting	`NCT06065995` - StoMakker Mobile Application	N/A
Recruiting	`NCT03282786` - Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease	N/A
Recruiting	`NCT06002074` - SMART Program Impact on Quality of Life in Inflammatory Bowel Diseases	N/A
Recruiting	`NCT04960826` - Study of an Environmental Risk Factor in Crohn's Disease
Recruiting	`NCT05413941` - Internet-based Cognitive Behavioral Therapy in Inflammatory Bowel Disease	N/A
Completed	`NCT03668249` - A Study to Characterize Multidimensional Model to Predict the Course of Crohn's Disease (CD)
Completed	`NCT00721812` - A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686	Phase 1
Recruiting	`NCT05809999` - IBD Neoplasia Surveillance RCT	N/A
Recruiting	`NCT04138225` - The Ecological Role of Yeasts in the Human Gut
Recruiting	`NCT04991324` - Cholecalciferol Comedication in IBD - the 5C-study	Phase 3
Completed	`NCT03173144` - Chronic Inflammatory Disease, Lifestyle and Treatment Response
Not yet recruiting	`NCT05043818` - A Clinical Study on the Screening of Intestinal Biomarkers in IBD Patients With Depression
Recruiting	`NCT03042091` - Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery	Early Phase 1
Not yet recruiting	`NCT02858557` - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases	N/A
Completed	`NCT02874365` - Intestinal Stem Cells Characterization	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Impact of Adalimumab Withdrawal or Continuation on Severity of COVID-19 and Risk of IMID Relapse — COV-ADA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms